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Psychotropic prescribing patterns among adolescents in Northern Ireland presenting with 
psychotic symptoms during a five-year period 
 
Abstract 
 
Objective: to report new prescriptions of psychotropic medications among adolescents presenting 
with new onset psychotic symptoms during a five-year period. 
Methods: The Northern Ireland Early Onset Psychosis Study (NIEOPS) is a naturalistic longitudinal 
observational study of patients with an early onset first psychotic episode. All patients aged less 
than 18 years presenting to specialist mental health services across Northern Ireland with new onset 
psychotic symptoms between 2001 and 2006 were recruited (n = 113). Clinical case notes were 
analysed retrospectively for details of subsequent treatment with psychotropic medications. 
Results: A total of 100 patients (88.5%) were prescribed some form of psychotropic medication. 
Over three-quarters of patients received an antipsychotic as their first medication. Risperidone 
(45.8%), olanzapine (24.0%) and chlorpromazine (12.5%) were the most commonly prescribed 
first-line antipsychotic medications. Of a total of 160 antipsychotic prescriptions, 81 (50.6%) were 
off-label. Prescriptions were most likely to have been deemed off-label due to medications not 
being licensed in under-18s (71.6% of off-label prescriptions) but other reasons were medications 
being used outside licensed age ranges (23.5%) and outside licensed indications (4.9%). 
Conclusions: This is the first study examining psychotropic prescribing patterns in a complete 
sample of all children and adolescents presenting with early onset psychotic episodes in a single 
geographical area. The observation of risperidone as the most commonly-prescribed antipsychotic 
was in keeping with previous studies in child and adolescent populations. Rates of off-label 
prescribing were lower than previously observed although our study was the first to investigate off-
label prescribing solely in children and adolescents presenting with psychotic symptoms. 
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Introduction 
 
Although antipsychotics are being used with increasing frequency in child and adolescent 
populations, it is acknowledged that little is known about the characteristics of those prescribed 
them (Olfson et al., 2006). Previous analyses of antipsychotic use in this age group have almost 
invariably included young persons being prescribed antipsychotics for a myriad of indications. We 
are only aware of one previous study looking at psychotropic prescribing patterns specifically in a 
child and adolescent first-episode psychosis population (Castro-Fornieles et al., 2008). 
 
The Northern Ireland Early Onset Psychosis Study is the first to investigate psychotic disorders in 
children and adolescents in this region of the United Kingdom (UK), mirroring the extensive body 
of work among the region’s adults in the Northern Ireland First Episode Psychosis Study (NIFEPS) 
(Barrett et al., 2009; Turkington et al., 2009). Northern Ireland’s total population in 2001 was 
1,685,267, of whom 451,514 (27.0%) were aged less than 18 years. The total UK population in 
2001 was 58,789,194. Northern Ireland has a higher proportion of young people under the age of 16 
(24%) than the UK average (20%). Specialist, or secondary care, child and adolescent mental health 
services (CAMHS) are provided throughout Northern Ireland across several sites and comprise both 
community and hospital facilities. Within the UK, secondary care services are provided by medical 
specialists who generally do not have first contact with patients, who have typically been referred to 
secondary care by their primary care provider (General Practitioner). 
 
Antipsychotic prescriptions in children and adolescents in the UK almost doubled between 1993 
and 2005 (Rani et al., 2008). This was driven by a large increase in the prescription of second-
generation antipsychotics, whereas the prescription of first-generation antipsychotics began to fall 
during the latter five years of this time period. The increase in antipsychotic prescribing among 
children and adolescents is even more dramatic in the United States (US) where two to six-fold 
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increases have been observed during similar time periods, with similar trends to those in the UK 
noted in the use of first- and second-generation preparations (Cooper et al., 2004; Aparasu et al., 
2005; Cooper et al., 2006; Olfson et al., 2006). 
 
The changing pattern of antipsychotic prescribing among children and adolescents has mainly been 
attributed to the less severe adverse effect profiles of the second-generation preparations, thereby 
allowing their use in situations where historically the first-generations’ risk-benefit ratio was not 
considered to favour the use of an antipsychotic (Olfson et al., 2006). Although the second-
generation antipsychotics have a lesser propensity for extra-pyramidal side effects they are 
associated with metabolic disturbance and weight gain, to which adolescents may be more 
vulnerable than their adult counterparts (Stigler et al., 2004; Pogge et al., 2005). Other factors 
suggested to have been involved in increasing antipsychotic prescribing are the expanding evidence 
base in relation to antipsychotic use in this age group (Harrison et al., 2012) and a lack of 
availability of non-pharmacological treatments (Thomas et al., 2006). 
 
It is noted that a growing number of antipsychotic prescriptions among children and adolescents are 
for 'off-label' use in the treatment of non-psychotic conditions such as conduct and behavioural 
disorders (Otasowie et al., 2010). Although accepted as commonplace in the general adult setting, 
the extent of off-label prescribing among children and adolescents in the UK is unknown (Baldwin 
and Kosky, 2007). At the time of our study there were few antipsychotics licensed for use in the 
under 18s, even in the presence of a diagnosed psychotic illness. The first-generation antipsychotics 
chlorpromazine and haloperidol were licensed for use in psychoses from very young ages and the 
second-generation antipsychotics amisulpride, sulpiride, clozapine and risperidone licensed for use 
in the mid-to-late teens. Olanzapine, quetiapine and the depot antipsychotic preparations were not 
licensed for use below the age of 18.  
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The NIEOPS is a multicentre naturalistic observational study designed to assess the clinical 
characteristics and interventions, both pharmacological and non-pharmacological, observed in 
children and adolescents presenting to specialist services with new onset psychotic symptoms in 
Northern Ireland. Psychotropic prescribing patterns and rates of off-label use of medication were 
studied, with particular interest afforded to antipsychotic prescriptions. The study was agreed and 
funded by the Northern Ireland Regional Multiprofessional Audit Group and the use of data 
collected as part of patients’ care was formally approved by all health care organisations involved 
for use in the study. 
 
Method 
 
At the time of conducting the study, Northern Ireland did not possess a case register for new onset 
psychotic episodes and we relied on clinician recall and cooperation for recruitment of potential 
subjects. CAMHS clinicians were appraised of the study in advance and requested to forward 
details of any person under the age of 18 years presenting to secondary care services with new onset 
psychotic symptoms such as delusions or hallucinations. All of the region’s consultants in general 
adult psychiatry were also contacted and requested to consider reporting eligible patients who had 
presented directly to adult services. 
 
Exclusion criteria were moderate intellectual disability (IQ < 50) or gross neurological disorder. 
Substance misuse was not an exclusion criterion. It is noted that psychotic symptoms have been 
observed to be common in childhood and not necessarily indicative of a psychotic illness. Such 
symptoms do not therefore prompt a referral to secondary care in all cases and as such we excluded 
all cases that were being monitored or managed in the primary care setting. 
 
A record was subsequently kept of children and adolescents presenting to secondary care mental 
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health services with new onset psychotic symptoms in Northern Ireland between 01 July 2001 and 
30 June 2006. Presentations were either to outpatient services or in several cases via direct hospital 
admission. Clinical case notes were subsequently analysed and information recorded for 
demographic variables, hospital admissions, involuntary admissions and both pharmacological and 
non-pharmacological interventions. Medications were classed as psychotropics if they were being 
used to treat a psychiatric condition or to ameliorate the side-effects of a psychotropic medication 
(such as antipsychotic-induced extrapyramidal side effects). Antiepileptics being used solely for the 
management of epilepsy were excluded from the study. 
 
The first new medication prescribed after presentation was accorded particular significance and its 
drug class recorded. Only regularly prescribed medications were recorded in this group and short-
term prescriptions or 'as required' medications excluded. If a medication was already being 
prescribed prior to assessment and it was deemed appropriate to continue this, this preparation was 
recorded as the first new medication. 
 
The first new antipsychotic, antidepressant, antiepileptic, benzodiazepine and 'other' medication 
(including mainly hypnotics and procyclidine, but also lithium) prescribed were recorded where 
applicable. Second and third line agents were recorded for the antipsychotic, antidepressant and 
other categories, and fourth line agents recorded for antipsychotics. 
 
In each case where psychotropic medication was prescribed, the British National Formulary (BNF) 
for children 2007 (Paediatric Formulary Committee, 2007)was used to determine whether or not 
this use was off-label. Medications were determined to have been prescribed off-label if they had 
been prescribed outside licensed indications, or outside the licensed age, dose or treatment duration 
ranges. 
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Statistical analysis 
 
Data were analysed using SPSS version 19.0 (IBM Corp., 2010). The Chi-square test was used to 
compare the frequency of both antipsychotic and antidepressant prescribing by gender. 
 
Results 
 
Patient characteristics 
 
A total of 113 subjects were identified during the five-year period. Mean age at first presentation 
with psychotic symptoms was 15.1 ± 1.7 years (range 10-17). 72 persons (63.7%) were male and 41 
(36.3%) female. 111 of 113 (98.2%) of patients were of Caucasian ethnicity. 26 of 113 (23.0%) 
patients had previously been in contact with mental health services. 83 of 113 (73.5%) patients were 
admitted to hospital at some point during the study period. Of those admitted to hospital, 36 
(43.4%) were involved in compulsory or detained admissions under the Mental Health (Northern 
Ireland) Order 1986. Diagnoses were unavailable for the full dataset and are not included in the 
study results. 
 
Non-pharmacological interventions 
 
A total of 67 patients (59.3%) received a psychological therapy treatment. In all, 36 patients 
(31.9%) received family work, 43 (38.1%) an educational intervention and 29 (25.7%) an 
occupational therapy intervention. 
 
Psychotropic medication prescribing 
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A total of 100 participants (88.5%) were prescribed some form of psychotropic medication (see 
Table 1). Retrospective analysis of the entire clinical case notes was not possible for all of the 113 
subjects as five volumes of notes were lost during a fire at one inpatient site. 
 
Of those patients prescribed psychotropic medication, 65% received an antipsychotic in isolation as 
the first type of medication prescribed, 14% received an antidepressant, 13% of patients were 
simultaneously commenced on both an antipsychotic and an antidepressant and 4% received a 
benzodiazepine as their first regularly prescribed medication (see Table 2). One patient received a 
stimulant medication as their first psychotropic. 
 
Antipsychotic prescribing 
 
In all, 96 patients (85.0%) were prescribed an antipsychotic at some point of the study (see Table 3). 
Of the first-line antipsychotics, risperidone (45.8%) was the most frequently prescribed, followed 
by olanzapine (24.0%) and chlorpromazine (12.5%). Risperidone (20.5%) was also the most 
commonly prescribed second-line antipsychotic, again followed by olanzapine and chlorpromazine 
(both 15.9%). Olanzapine and clozapine (both 20.0%) were the most commonly prescribed third-
line antipsychotics, followed by aripiprazole (15.0%), amisulpride and haloperidol (both 10.0%). 
Risperidone (33.3%) was the most commonly prescribed of the fourth-line antipsychotics, followed 
by chlorpromazine (22.2%). Two of the three risperidone prescriptions at this stage were for the 
medication’s intramuscular depot preparation. With the exception of cross-titration periods, there 
were no instances of more than one antipsychotic being prescribed simultaneously. 
 
Antidepressant prescribing 
 
A total of 43 patients (38.1%) were prescribed an antidepressant during the study period (see Table 
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4). Fluoxetine (48.8%) was the most frequently prescribed of the first-line antidepressants, followed 
by sertraline (23.3%), mirtazapine and citalopram (both 9.3%). Sertraline (46.2%) was the most 
frequently prescribed second-line antidepressant, followed by fluoxetine and mirtazapine (both 
15.4%) and clomipramine, dosulepin and venlafaxine (all 7.7%). Venlafaxine (33.3%) was the most 
commonly prescribed third-line antidepressant, followed by dosulepin, lofepramine, mirtazapine 
and sertraline (all 16.7%). 
 
Prescribing of other psychotropic medications 
 
Sodium valproate (70.8%) was the most commonly prescribed first-line antiepileptic. 
Carbamazepine (12.5%), lamotrigine (12.5%) and gabapentin (4.2%) were prescribed with lesser 
frequencies. 
 
Diazepam (52.4%) accounted for more than half of first-line benzodiazepine prescriptions, 
lorazepam (38.1%) and temazepam (9.5%) making up the remainder. 
There was a wide range of first ‘other’ medications prescribed, half of which were accounted for by 
lithium and procyclidine (see Table 5). 
 
Off-label psychotropic medication prescribing 
 
Rates of off-label prescribing among the antipsychotic medications remained largely stable at 
around 55% as patients moved from first to fourth-line agents (see Table 6). 
 
Antidepressant prescribing was entirely off-label, as was the use of benzodiazepines and 
antiepileptics. Almost two-thirds (65.4%) of the first ‘other’ medications were off-label 
prescriptions. 
10 
 
 
We looked in particular at reasons for the antipsychotic prescriptions being deemed to be off-label, 
categorising them as such for one of four main reasons: (i) not licensed at all in under-18s; (ii) 
prescribed outside licensed age range; (iii) prescribed outside licensed indication(s); (iv) prescribed 
outside licensed dose range (Table 7). 
 
Of the 81 off-label prescriptions, 58 (71.6%) were for preparations not licensed at all in under-18s, 
the majority of such prescriptions being accounted for by olanzapine and quetiapine. A further 19 
(23.5%) prescriptions were for medications being used outside (more specifically below) the 
licensed age range. Four (4.9%) prescriptions were for medications being used outside their 
licensed indications (see Table 7). 
 
Psychotropic prescribing by gender 
 
We tested for an association between gender and the prescription of either antipsychotics or 
antidepressants. Although antipsychotics were prescribed more frequently among males (83.3% of 
males and 68.3% of females) and antidepressants more frequently among females (31.9% of males 
and 48.8% of females), a Chi-square test for independence (with Yates Continuity Correction) 
indicated no significant association between gender and the prescription of either antipsychotics, χ2 
(1, n = 113) = 2.6, p = .11, phi = -.17 or antidepressants χ2 (1, n = 113) = 2.5, 
p = .12, phi = .17. 
 
 
 
 
Discussion 
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As the first study to examine psychotropic prescribing patterns in a complete sample of children and 
adolescents presenting with early onset psychotic episodes in a single geographical area, our paper 
provides an invaluable overview of characteristic treatments, particularly psychotropic prescribing 
patterns, in this population during a recent five-year time period. The age profile of our study group 
was almost identical to that observed in a similar study of 110 adolescents with early onset 
psychosis by the CAFEPS group in Spain(Castro-Fornieles et al., 2008). The 2:1 male to female 
ratio we observed had previously been seen in a study of children and adolescents presenting to 
outpatients and being prescribed antipsychotics in a large cross-sectional analysis in the US 
(Aparasu and Bhatara, 2007). It has been demonstrated elsewhere that adolescent males are more 
than twice as likely to be prescribed antipsychotics as their female counterparts (Olfson et al., 
2006). Such patterns are in keeping with the earlier average age of onset of schizophrenia in males 
(15-25 years) than females (25-35 years) (Hafner et al., 1994). 
 
Our observation that over three-quarters of persons were prescribed an antipsychotic as their first 
new medication (either alone or in combination with an antidepressant) was understandable given 
that all of our study participants were referred due to new onset psychotic symptoms. The high rates 
of hospital admissions and detentions under the Mental Health (Northern Ireland) Order 1986 were 
reflective of the high levels of morbidity among our study population. 
 
Risperidone has repeatedly been demonstrated to be the most commonly prescribed antipsychotic 
among child and adolescent populations (Pappadopulos et al., 2002; Doerry and Kent, 2003; 
Sivaprasad et al., 2006; Aparasu and Bhatara, 2007; Castro-Fornieles et al., 2008; Haw and Stubbs, 
2010) and our finding of risperidone as the most commonly prescribed of both the first- and second-
line antipsychotics was consistent with such studies. The frequency of risperidone prescribing 
would appear to be attributable to the fact that it was the only one of the more commonly used 
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second-generation antipsychotics to be licensed in the under-18s (possessing a licence for use 
between 15-18 years), with both olanzapine and quetiapine not licensed at all among this age group. 
The three most commonly prescribed first-line antipsychotics observed in our study accounted for 
over 80% of prescriptions and were risperidone (45.8%), olanzapine (24.0%) and chlorpromazine 
(12.5%). Three antipsychotic medications accounted for more than three-quarters of antipsychotic 
prescriptions in the CAFEPS group’s baseline findings, with risperidone (45.5% of patients), 
quetiapine (16.4%) and olanzapine (14.5%) predominating (Castro-Fornieles et al., 2008). The 
CAFEPS study was conducted during the two year period 2003-2005 which fell within the time 
limits of our study. 
 
First-generation antipsychotics accounted for 14.6% of first-line antipsychotic prescriptions in our 
study, a higher proportion than we had envisaged. Of the 14 prescriptions for first-generation 
antipsychotics, 12 (85.7%) were for chlorpromazine. Haloperidol was the only first-generation 
antipsychotic prescribed at baseline in the CAFEPS group, where it was used in only 1.8% of 
persons(Castro-Fornieles et al., 2008). A cross-sectional analysis of outpatient child and adolescent 
antipsychotic prescriptions in the US showed rates of first-generation antipsychotic prescribing of 
only 1.0% (Aparasu and Bhatara, 2007), although an earlier analysis between 2000-2002 
demonstrated a rate of 7.7% (Olfson et al., 2006). We considered whether the chlorpromazine use in 
our study was clustered in one particular centre and reflective of individual rather than collective 
practice but were unable to determine this retrospectively from analysis of the anonymised data. 
Other possible explanations for the preponderance of chlorpromazine prescribing may have 
included the fact that it is licensed for use even in very young children (from 1 year) and the long 
period of clinician experience and familiarity of use that is associated with long-established 
preparations, with both factors likely to reduce prescriber anxiety regarding its use. 
 
We were surprised to see zuclopenthixol, as a relatively uncommonly used first-generation 
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antipsychotic, among the first-line antipsychotic medications. It is however important to consider 
that we studied medication prescriptions after presentation with new onset psychotic symptoms, 
rather than first exposure to any antipsychotic medication. A large proportion (23.0%) of persons in 
our study had had prior contact with mental health services and may have previously been exposed 
to one or more antipsychotics for the treatment of non-psychotic conditions. It is also feasible that 
subjects may have previously had antipsychotics prescribed at primary care level. We believe that it 
is therefore unlikely that this prescription was that person’s first exposure to antipsychotic 
medication. 
 
The increasing use of clozapine and antipsychotic long-acting injections with each successive 
change of medication was similar to patterns expected among adult populations and is reflective of 
treatment resistance and concerns regarding medication non-compliance. 
 
The predominance of the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and sertraline 
among the first and second-line antidepressants was in keeping with the findings of previous studies 
(Shireman et al., 2002). During our study period, in 2003, the Committee on Safety of Medicines 
(CSM) advised against the use of paroxetine in depressed children and adolescents due to an 
association with increased suicidal ideation (Duff, 2003). Paroxetine was not prescribed to any of 
our study participants. A similar warning was subsequently issued in late 2004 by the Medicines 
and Healthcare products Regulatory Agency (MHRA) regarding all SSRIs except fluoxetine, 
although the SSRIs' association with suicide was not statistically significant (Weller et al., 2004). A 
2004 meta-analysis of published and unpublished data for SSRI use in children highlighted 
fluoxetine as the only SSRI with a consistently favourable risk-benefit profile (Whittington et al., 
2004). 
 
Rates of off-label antipsychotic prescribing were significantly lower than might be expected from 
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the previous, admittedly sparse, literature.  Of a total of 160 antipsychotic prescriptions, 81 (50.6%) 
were off-label. This is explained by the diagnosis of a psychotic illness in the vast majority of cases 
in which antipsychotics were prescribed in our study, thereby allowing almost half of prescriptions 
to fall within the marketing authorisations of the prescribed medication. In their study of off-label 
prescribing of psychotropic medications in an adolescent medium secure unit, Haw and Stubbs 
(Haw and Stubbs, 2010) found 59 of 68 (86.8%) antipsychotic prescriptions to be off-label. The 
more common diagnoses among this group however included mild intellectual disability, autistic 
spectrum disorders and complex post-traumatic stress disorder, with schizophrenia and affective 
psychoses much less common. Medication was most frequently prescribed off-label in this group 
for behavioural indications and the management of aggression. 
 
Despite the lower than anticipated rate of off-label prescribing observed in our study, it remained 
high, encompassing more than half of all antipsychotic prescriptions. Even among the first-line 
antipsychotics, at which point in the prescribing process there would have been several licensed 
options that had not been tried previously, 47 of 87 prescriptions (54.0%) were off-label. Almost 
three-quarters of all off-label antipsychotic prescriptions in our study were for medications (mainly 
the second-generation antipsychotics olanzapine and quetiapine) not licensed for use at all among 
under-18s. We note that the National Institute for Health and Care Excellence’s (NICE) Technology 
Appraisal Guidance 43 on second-generation antipsychotics (National Institute for Health and Care 
Excellence, 2002a) and the organisation’s first Clinical Guidelines document on schizophrenia 
(National Institute for Health and Care Excellence, 2002b) were both published toward the 
beginning of our study period. Although neither document provided specific advice regarding the 
use of antipsychotics in under-18s, both provided formalised guidance regarding the preferential use 
of second-generation antipsychotics (specifically amisulpride, olanzapine, quetiapine, risperidone 
and zotepine) as first-line treatments of psychotic illnesses due to a reduced incidence of adverse 
side effects compared to first-generation antipsychotics. It would not be unreasonable to expect that 
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this advice had an impact on prescribing patterns among child and adolescent psychiatrists. 
 
Our study has several weaknesses. Although it was reasonably sized, recruitment relied on clinician 
recall and cooperation, and there exists a possibility that there may have been cases missed during 
the five-year study period. We are confident for several reasons however that there will have been 
few such missed cases. Psychotic symptoms of sufficient severity to warrant referrals to CAMHS 
are relatively rare and therefore memorable, and as such any presentation is likely to have prompted 
registration with our study. Extensive efforts were made to regularly visit the various CAMHS 
centres both before and during the study period to ensure comprehensive and thorough recruitment 
of eligible patients. 
 
We were unable to ascertain which psychotropic medications subjects had been exposed to prior to 
our study. This information would have been of value when considering the prescription of the less-
commonly used antipsychotic medications, such as the apparent unusually early use of 
zuclopenthixol discussed above. 
 
The lack of prescription of any psychotropic medication in 8 of the 113 persons (7.1%) would 
suggest that they were not ultimately deemed to be suffering from a psychotic illness; though they 
were initially thought to be presenting with psychotic symptoms. It is also possible that some 
patients may simply have been unwilling to accept medications. Had we had diagnoses available for 
the full dataset this could have been further explored. 
 
Our study did not track the duration of prescription of each antipsychotic, or reasons for switching 
or discontinuation. Such data would have been useful for comparison with the CAFEPS follow up 
paper (Noguera et al., 2013), which demonstrated high antipsychotic discontinuation rates of 44.5% 
at six months, 59.1% at 12 months, and 70.9% at 24 months. 
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It is possible that prescribing patterns have changed in the time period since the completion of our 
analysis due to the withdrawal from use of agents such as zotepine and the emergence of new 
preparations (paliperidone, asenapine). Anecdotal evidence would point to the growth in the use of 
quetiapine and aripiprazole among children and adolescents during this time period, the latter of 
which is licensed for use in the over-15s. It is clear that little research into the use of psychotropics 
in children and adolescents has been carried out to date and we agree with previous authors who 
have called urgently for further research into the use of psychotropic medication in this age group 
(Olfson et al., 2006; Verdoux et al., 2010). 
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Table 1 Frequency of psychotropic medication prescribing 
 
Medication Prescribed Frequency Percentage 
Yes 100 88.5 
No 8 7.1 
Unknowna 5 4.4 
 113 100 
 
aRetrospective analysis of all 113 patients’ clinical case notes was not possible due to the destruction of five 
volumes of notes in a fire. 
 
Table 2 Breakdown of first new psychotropic prescriptions by class 
 
First New Medication (Class) Frequency Percentage
Antipsychotic 65 65 
Antidepressant 14 14 
Antipsychotic and antidepressant 13 13 
Benzodiazepine 4 4 
Stimulant 1 1 
Unknowna 3 3 
 100 100 
 
aIt was impossible to determine the first class of medication prescribed in three patients due to the 
destruction of the clinical notes. 
 
Table 3 Patterns of antipsychotic (AP) prescribing, from first to fourth-line agents 
 
Antipsychotic (AP) 
First AP 
Frequency 
First AP 
Percentage 
Second AP 
Frequency 
Second AP 
Percentage 
Third AP 
Frequency 
Third AP 
Percentage 
Fourth AP 
Frequency 
Fourth AP 
Percentage 
Amisulpride 2 2.1 5 11.4 2 10     
Aripiprazole     2 4.5 3 15     
Chlorpromazine 12 12.5 7 15.9 1 5 2 22.2 
Clozapine     4 9.1 4 20 1 11.1 
FlupentixolDecanoate 
    
1 2.3 1 5     
FluphenazineDecanoate 
    
    1 5     
Haloperidol 1 1 2 4.5 2 10     
Olanzapine 23 24 7 15.9 4 20 1 11.1 
Quetiapine 4 4.2 4 9.1 1 5     
Risperidone 44 45.8 9 20.5 1 5 3 33.3 
Sulpiride     2 4.5         
Zotepine     1 2.3     1 11.1 
Zuclopenthixol 1 1         1 11.1 
Unknowna 9 9.4             
Total 96 100 44 100 20 100 9 100 
 
AP, antipsychotic 
aIt was impossible to determine the first AP prescribed in nine cases, due to either the destruction of clinical 
notes or the quality of the clinical records. 
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Table 4 Patterns of antidepressant (AD) prescribing, from first to third-line agents 
 
First 
Antidepressant 
(AD) 
First 
Antidepressant 
Frequency 
First 
Antidepressant 
Percentage 
Second 
Antidepressant 
Frequency 
Second 
Antidepressant 
Percentage 
Third 
Antidepressant 
Frequency 
Third 
Antidepressant 
Percentage 
Citalopram 4 9.3         
Clomipramine     1 7.7     
Dosulepin     1 7.7 1 16.7 
Escitalopram 2 4.7         
Fluoxetine 21 48.8 2 15.4     
Lofepramine         1 16.7 
Mirtazapine 4 9.3 2 15.4 1 16.7 
Sertraline 10 23.3 6 46.2 1 16.7 
Venlafaxine 2 4.7 1 7.7 2 16.7 
Total 43 100 13 100 6 100 
 
Table 5 Patterns of prescribing of first ‘other’ medications 
 
First Other Medication Frequency Percentage 
Atomoxetine 3 12 
Buspirone 3 12 
Lithium 5 25 
Melatonin 2 8 
Procyclidine 5 25 
Zolpidem 3 12 
Zopiclone 4 16 
 25 100 
 
Table 6 Levels of off-label antipsychotic prescribing, from first to fourth-line agents 
 
Medication Percentage of prescriptions off-label
First Antipsychotic 54 
Second Antipsychotic 40.9 
Third Antipsychotic 55 
Fourth Antipsychotic 55.6 
 
Table 7 Off-label antipsychotic prescriptions by reason adjudged to be off-label 
 
Reason prescription adjudged to be off-label Frequency Percentage 
Not licensed at all in under-18s 58 71.6 
Prescribed outside licensed age range 19 23.5 
Prescribed outside licensed indication(s) 4 4.9 
Prescribed outside licensed dose range 0 0 
 81 100 
 
